v3.26.1
Revenues
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
Product Revenues
The Company accounts for revenues from contracts with customers under ASC 606.
The Company’s net revenues consisted of the following for the three and six months ended June 30, 2026 and 2025:
Three months ended June 30,Six months ended June 30,
2026202520262025
Products:
Talicia$2,349,890 $— $4,266,370 $— 
Sancuso1,816,737 3,119,112 4,745,372 4,079,920 
Vibativ1,738,887 2,701,854 3,857,183 6,238,609 
Kristalose1,061,442 2,754,299 2,042,926 5,375,405 
Caldolor1,474,288 1,588,293 2,439,852 2,895,733 
Acetadote136,661 193,544 188,643 345,195 
Vaprisol— (14,621)518 (15,221)
Omeclamox-Pak— (752)— (6,139)
RediTrex1,802 3,244 1,311 2,897 
Other revenue221,534 492,390 390,384 3,634,019 
Total revenue8,801,241 $10,837,363 17,932,559 22,550,418 
Less discontinued operations(8,634,783)$(10,456,566)$(17,602,251)$(22,002,993)
Revenue from continuing operations$166,458 $380,797 $330,308 $547,425 
On July 1, 2026, the Company completed the closing of the Strategic Transaction with Apotex selling these branded products. We are classifying the revenues from these branded products as discontinued operations.
For the three and six months ended June 30, 2026 and 2025, the amounts noted with regard to Vaprisol, Omeclamox-Pak and RediTrex, resulted from routine sales deduction adjustments of these products which had no sales for the periods represented.
Other Revenues
In early 2025, Cumberland received a $3.0 million milestone payment from our distribution partner in China associated with the approval of Vibativ for that market. The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
Other revenues also include lease income generated by CET’s Life Sciences Center, which is a research facility that provides scientists with access to flexible lab space and other resources to develop biomedical products. This lease income, as noted in Footnote 5 - Leases, was approximately $0.2 million for the three months ended June 30, 2026 and 2025, and $0.3 million for the six months ended June 30, 2026 and 2025.